Validation of a multi-gene qPCR-based pharmacogenomics panel across major ethnic groups in Singapore and Indonesia / Anar Sanjaykumar Kothary, Caroline Mahendra, Mingchen Tan, Eunice Jia Min Tan, Jacelyn Phua Hong Yi, Gabriella , Tan Xin Hui Jocelyn, Jessline Stephanie Haruman, Zhihao Tan, Chun Kiat Lee, Alexander Lezhava, Benedict Yan, Astrid Irwanto
Aim:The clinical utility of pharmacogenomics (PGx) has been gaining traction alongside growing evidence that adverse drug reactions (ADRs) have significant genetic associations. Nala PGx Core®is a multi-gene qPCR-based panel of 20 allele variants, comprising 18 SNPs and twoCYP2D6copy number markers across four pharmacogenes –CYP2C9,CYP2C19,CYP2D6andSLCO1B1.Methods:In this study, we validated the performance of Nala PGx Core®against benchmark methods, on the Singaporean and Indonesian populations.Results & conclusion:Nala PGx Core®demonstrated robust and accurate genotyping when compared with other established benchmarks. Furthermore, the panel successfully characterized alleles of clinical relevance, such asCYP2D6*10andCYP2D6*36, across major ethnic groups present of Singapore and Indonesia, suggesting its potential for adoption in clinical workflows regionally. Aim: ® CYP2D6 CYP2C9 CYP2C19 CYP2D6 SLCO1B1 Methods: ® Results & conclusion: ® CYP2D6*10 CYP2D6*36.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2021 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kothary, Anar Sanjaykumar [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Adverse drug reactions |
|---|
| Umfang: |
1 Online-Ressource (16 p) |
|---|
| doi: |
10.2217/pgs-2021-0071 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011091150 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011091150 | ||
| 003 | DE-627 | ||
| 005 | 20231109205957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2021-0071 |2 doi | |
| 035 | |a (DE-627)KFL011091150 | ||
| 035 | |a (KFL)prod_FICIBQ_10.2217/pgs-2021-0071 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Kothary, Anar Sanjaykumar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Validation of a multi-gene qPCR-based pharmacogenomics panel across major ethnic groups in Singapore and Indonesia |c Anar Sanjaykumar Kothary, Caroline Mahendra, Mingchen Tan, Eunice Jia Min Tan, Jacelyn Phua Hong Yi, Gabriella , Tan Xin Hui Jocelyn, Jessline Stephanie Haruman, Zhihao Tan, Chun Kiat Lee, Alexander Lezhava, Benedict Yan, Astrid Irwanto |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2021 | |
| 300 | |a 1 Online-Ressource (16 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim:The clinical utility of pharmacogenomics (PGx) has been gaining traction alongside growing evidence that adverse drug reactions (ADRs) have significant genetic associations. Nala PGx Core®is a multi-gene qPCR-based panel of 20 allele variants, comprising 18 SNPs and twoCYP2D6copy number markers across four pharmacogenes –CYP2C9,CYP2C19,CYP2D6andSLCO1B1.Methods:In this study, we validated the performance of Nala PGx Core®against benchmark methods, on the Singaporean and Indonesian populations.Results & conclusion:Nala PGx Core®demonstrated robust and accurate genotyping when compared with other established benchmarks. Furthermore, the panel successfully characterized alleles of clinical relevance, such asCYP2D6*10andCYP2D6*36, across major ethnic groups present of Singapore and Indonesia, suggesting its potential for adoption in clinical workflows regionally. Aim: ® CYP2D6 CYP2C9 CYP2C19 CYP2D6 SLCO1B1 Methods: ® Results & conclusion: ® CYP2D6*10 CYP2D6*36 | ||
| 653 | |a adverse drug reactions | ||
| 653 | |a CYP2C19 | ||
| 653 | |a CYP2C9 | ||
| 653 | |a CYP2D6 | ||
| 653 | |a genetic associations | ||
| 653 | |a genomic DNA | ||
| 653 | |a molecular diagnostics | ||
| 653 | |a SLCO1B1 | ||
| 653 | |a Southeast Asia | ||
| 700 | 1 | |a Mahendra, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Mingchen |e verfasserin |4 aut | |
| 700 | 1 | |a Min Tan, Eunice Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Hong Yi, Jacelyn Phua |e verfasserin |4 aut | |
| 700 | 1 | |a Hui Jocelyn, Tan Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Haruman, Jessline Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Zhihao |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Chun Kiat |e verfasserin |4 aut | |
| 700 | 1 | |a Lezhava, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Benedict |e verfasserin |4 aut | |
| 700 | 1 | |a Irwanto, Astrid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d London [u.a.] : Ashley, 2000 |h Online-Ressource |w (DE-627)KFL00000605X |w (DE-600)2030168-6 |w (DE-576)398099871 |x 1744-8042 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.2217/pgs-2021-0071 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||